Monthly Archives: May 2012

Drug Patent Expirations in May 2012

*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
LIDODERM Teikoku Pharma Usa lidocaine 5,601,838 May 2, 2012
LIDODERM Teikoku Pharma Usa lidocaine 5,411,738 May 2, 2012
TRAVATAN Z Alcon Pharms Ltd travoprost 6,503,497 May 6, 2012
TRAVATAN Z Alcon Pharms Ltd travoprost 6,849,253 May 6, 2012
CRIXIVAN Merck Sharp Dohme indinavir sulfate 5,413,999 May 9, 2012
ALLEGRA Sanofi Aventis Us fexofenadine hydrochloride 6,399,632 May 11, 2012
CHILDREN’S ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 6,399,632 May 11, 2012
CHILDREN’S ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 6,399,632 May 11, 2012
ALLEGRA Sanofi Aventis Us fexofenadine hydrochloride 6,187,791 May 11, 2012
CHILDREN’S ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 6,187,791 May 11, 2012
CHILDREN’S ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 6,187,791 May 11, 2012
AGGRASTAT Medicure tirofiban hydrochloride 5,292,756 May 14, 2012
COMBIVIR Viiv Hlthcare lamivudine; zidovudine 5,859,021 May 15, 2012
PLAVIX Sanofi Aventis Us clopidogrel bisulfate 4,847,265*PED May 17, 2012
ACTONEL WITH CALCIUM (COPACKAGED) Warner Chilcott calcium carbonate; risedronate sodium 6,096,342*PED May 21, 2012
IMODIUM MULTI-SYMPTOM RELIEF Mcneil loperamide hydrochloride; simethicone 5,716,641 May 21, 2012
VIRAMUNE Boehringer Ingelheim nevirapine 5,366,972*PED May 22, 2012
ACTONEL Warner Chilcott risedronate sodium 6,096,342*PED May 22, 2012
VIRAMUNE XR Boehringer Ingelheim nevirapine 5,366,972*PED May 22, 2012
Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com